Effects of Ginkgo diterpene lactone gluconate injection combined with vascular recanalization on patients with large-vessel occlusive cerebral infarction: A clinical observation study

This study aims to evaluate the clinical efficacy and safety of combining Ginkgo diterpene lactone glucoside injection with endovascular recanalization therapy in patients with large-vessel occlusive cerebral infarction. A total of 80 patients with large-vessel occlusive cerebral infarction who underwent endovascular treatment in the Department of Neurology from January 2021 to December 2022 were selected for this study. The patients were randomly divided into an observation group (n = 40) and a control group (n = 40). The observation group received endovascular recanalization therapy combined with Ginkgo diterpene lactone glucoside injection for 7 days, while the control group received endovascular recanalization therapy without the addition of Ginkgo diterpene lactone glucoside injection. This study assessed the prognosis of both groups after 90 days of treatment. Before treatment, there was no statistically significant difference between the 2 groups in baseline characteristics, such as neurological function (National Institutes of Health Stroke Scale score). However, after 90 days of treatment, there was a significant difference in National Institutes of Health Stroke Scale scores between the observation group and the control group (4.94 ± 3.65 vs 7.74 ± 6.46, P = .033). Although there was no statistically significant difference in the proportion of patients with good prognosis (Modified Rankin Scale (mRS) score 0-2) after 90 days of treatment (P = .072), the proportion of patients with good prognosis in the observation group was higher than that in the control group (65% vs 45%). After 90 days of treatment, there was also no statistically significant difference in the proportion of patients with poor prognosis (mRS score 5-6, where 6 points indicate death) (P = .084). However, the proportion of patients with poor prognosis in the observation group was lower than that in the control group (20% vs 37.5%). The comparisons of symptomatic intracranial hemorrhage, malignant cerebral edema, and mortality rates between the 2 groups after treatment did not show statistically significant differences (all P > .05). For patients with large-vessel occlusive cerebral infarction who have undergone endovascular recanalization therapy, the combined use of Ginkgo diterpene lactone glucoside injection can effectively improve neurological function and may enhance quality of life without increasing the risk of symptomatic intracranial hemorrhage. No statistically significant reduction in mortality was observed.